Please ensure Javascript is enabled for purposes of website accessibility

InterMune Inc. ASCENDs to Greatness

By Brian Orelli, PhD - Feb 26, 2014 at 9:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

InterMune succeeds where Gilead and Novartis failed. Its IPF drug Esbriet looks destined for approval.

Third time is the charm for InterMune (ITMN.DL). Of course, so was the first.

It was the middle trial that ended up delaying a U.S. approval for its lung drug Esbriet by five years.

Haven't been following biotech for that long? Let's get you caught up.

  • In 2009, the biotech said Esbriet helped patients in both trials, but only one of the two phase 3 trials in a lung disease called idiopathic pulmonary fibrosis demonstrated a statistically significant difference between Esbriet and placebo.
  • An FDA advisory committee voted 9-3 recommending approval of the drug.
  • The FDA ignored its outside advisors and rejected the drug.
  • EU regulators were more forgiving of the mixed data and approved Esbriet.

Source: InterMune.

InterMune went back to the drawing board, designing a new clinical trial, dubbed ASCEND, with more patients than the first two trials to improve the chances of showing statistical significance. The company also measured efficacy at 52 weeks rather than 72 weeks in the previous trials, because the trials showed a treatment effect at 48 weeks, but then the placebo group didn't decline as fast as the Esbriet group so, by 72 weeks, the difference wasn't statistically significant. InterMune also tweaked the primary endpoint; instead of comparing the relative decline in lung capacity -- called percent predicted forced vital capacity, or FVC -- the new trial measured how many patients saw a 10% decline in FVC, which is clinically meaningful.

The changes worked. Big time.

After a year on the drug, 16.5% of patients experienced an FVC decline of 10% or more (patients that died were also included) compared to 31.8% of patients that took placebo. The difference had a p-value of less than 0.000001. Or in other words, there's a 0.0001% chance that the difference happened by chance alone.

Yeah, I'd call that statistically significant.

Ironically, the relative change in FVC was statistically significant as well, so InterMune didn't really have to change the endpoint. Of course, maybe that shouldn't be too surprising since Esbriet did pass one of the two trials with that endpoint.

InterMune plans to submit its new application to the FDA in the third quarter. As far as I can tell, the data looks good enough to get approved by the FDA this time around.

Was the FDA wrong?
Clearly.

In hindsight, at least.

The main argument at the advisory committee meeting seemed to be that there weren't any approved treatments for IPF, so why not just approve it despite the mixed data? As much as investors and companies would like, that's generally not how the FDA works.

While I hate defending the FDA's overly cautious stance, I think the agency was right to be careful with Esbriet considering how hard it's been to treat IPF. In the intervening five years since Esbriet's last trials, a trial for Gilead Sciences' (GILD 0.83%) ambrisentan was stopped because of lack of efficacy; Actelion Pharmaceuticals' Tracleer failed to show an effect in IPF, and so did Novartis' (NVS 0.43%) Gleevec. 

There was a report from an unnamed source that Boehringer Ingelheim's nintedanib has passed a phase 3 trial, but the company hasn't confirmed that, as far as I know. Both companies should report data at the American Thoracic Society in May, so we'll know soon enough who might win in the marketplace, assuming they're both approved.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

InterMune, Inc. Stock Quote
InterMune, Inc.
ITMN.DL
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.60 (0.83%) $0.51
Novartis AG Stock Quote
Novartis AG
NVS
$85.94 (0.43%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.